Kyle Gano is Chief Executive Officer and Director of Neurocrine BioSciences Inc (NBIX). The company reported total compensation of $13,448,935 for fiscal year 2025.
| Salary | $920,000 |
|---|---|
| Bonus | $966,000 |
| Stock awards | $5,750,023 |
| Option awards | $5,750,006 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $62,906 |
| Total | $13,448,935 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Neurocrine BioSciences Inc filed April 15, 2026, accession 0000914475-26-000015.
| Peer-group chief executive median | $17,943,521 |
|---|---|
| Difference from that median | $-4,494,586 |
| Percentile within the disclosed peer group | 33rd |
| Peers with a disclosed figure | 15 |
Medians and percentiles are computed across the peer group Neurocrine BioSciences Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kyle Gano this page | Chief Executive Officer and Director | $13,448,935 |
| Sanjay Keswani | Chief Medical Officer | $9,007,803 |
| Jude Onyia | Chief Scientific Officer | $7,410,769 |
| Matthew Abernethy | Chief Financial Officer | $6,311,912 |
| Eiry Roberts | Strategic Advisor | $6,073,032 |
| Eric Benevich | Chief Commercial Officer | $5,888,947 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Neurocrine BioSciences Inc compensation brief.
Kyle Gano's compensation sits inside Neurocrine BioSciences Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.